About: Relapsed follicular lymphoma sequentially treated with ritusimab and 90-Y-ibritumomab tiuxetan

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Relapsed follicular lymphoma sequentially treated with ritusimab and 90-Y-ibritumomab tiuxetan Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	Monoclonal antibodies have dramatically changed the treatment possibilities for follicular lymphoma. 90Y-ibritumomab tiuxetan (Zevalin?) is the first radioimmunotherapy agent approved for the treatment of relapsed and resistant follicular lymphoma patients. Long-term benefi t was observed especially for patients achieving CR after radioimmunotherapy. Monoclonal antibodies have dramatically changed the treatment possibilities for follicular lymphoma. 90Y-ibritumomab tiuxetan (Zevalin?) is the first radioimmunotherapy agent approved for the treatment of relapsed and resistant follicular lymphoma patients. Long-term benefi t was observed especially for patients achieving CR after radioimmunotherapy. (en) Monoklonální protilátky dramaticky změnily možnosti léčby folikulárního lymfomu. 90Y-ibritumomab tiuxetan (Zevalin?) je první radioimunologický prostředek schválený pro léčbu pacientů s recidivujícím a rezistentním folikulárním lymfomem. (cs)
Title	Relapsed follicular lymphoma sequentially treated with ritusimab and 90-Y-ibritumomab tiuxetan Relapsed follicular lymphoma sequentially treated with ritusimab and 90-Y-ibritumomab tiuxetan (en) Recidivující folikulární lymfom následně léčený ritusimabem a 90-Y-ibritumomab tiuxetanem. (cs)
skos:prefLabel	Relapsed follicular lymphoma sequentially treated with ritusimab and 90-Y-ibritumomab tiuxetan Relapsed follicular lymphoma sequentially treated with ritusimab and 90-Y-ibritumomab tiuxetan (en) Recidivující folikulární lymfom následně léčený ritusimabem a 90-Y-ibritumomab tiuxetanem. (cs)
skos:notation	RIV/61989592:15110/07:00004014!RIV08-MZ0-15110___
http://linked.open.../vavai/riv/strany	109-112
http://linked.open...avai/riv/aktivita	P Z
http://linked.open...avai/riv/aktivity	P(NR9502), Z(MSM6198959205)
http://linked.open...iv/cisloPeriodika	1
http://linked.open...vai/riv/dodaniDat	2008
http://linked.open...aciTvurceVysledku	Raida, Luděk PAPAJÍK, Tomáš MYSLIVEČEK, Miroslav INDRÁK, Karel Procházka, Vít Kučerová, Ladislava Kubová, Zuzana
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Univerzita Palackého v Olomouci / Lékařská fakulta
http://linked.open...dnocenehoVysledku	447146
http://linked.open...ai/riv/idVysledku	RIV/61989592:15110/07:00004014
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	Follicular lymphoma; Ibritumomab tiuxetan; Rituximab; CD20 antigen; Therapy; Positron emission tomography (en)
http://linked.open.../riv/klicoveSlovo	Therapy Follicular lymphoma Rituximab Ibritumomab tiuxetan Positron emission tomography CD20 antigen
http://linked.open...odStatuVydavatele	CZ - Česká republika
http://linked.open...ontrolniKodProRIV	[52A7DB0F24A6]
http://linked.open...i/riv/nazevZdroje	Biomedical Papers
http://linked.open...in/vavai/riv/obor	FD
http://linked.open...ichTvurcuVysledku	7 (xsd:int)
http://linked.open...cetTvurcuVysledku	9 (xsd:int)
http://linked.open...vavai/riv/projekt	Integrated 2-[fluorine-18] fluoro-2-deoxy-D-glucose positron emission tomography with computer tomography as basic imaging method for the evaluation of non-Hodgkin´s lymphoma patients
http://linked.open...UplatneniVysledku	2007
http://linked.open...v/svazekPeriodika	151
http://linked.open...iv/tvurceVysledku	Indrák, Karel Kubová, Zuzana Raida, Luděk Procházka, Vít Kučerová, Ladislava Papajík, Tomáš Buriánková, Eva Mysliveček, Miroslav Drymlová, Jaroslava
http://linked.open...n/vavai/riv/zamer	Studies of genes and molecular mechanisms involved in regulation of hematopoiesis, their clinical impact and targeted treatment
issn	1213-8118
number of pages	4 (xsd:int)
http://localhost/t...ganizacniJednotka	15110

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 49 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software